Skip to main content

Advertisement

Log in

Prevention of Epilepsy: Issues and Innovations

  • Epilepsy (CW Bazil, Section Editor)
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Epilepsy is a common brain disease and preventing epilepsy is a very relevant public health concern and an urgent unmet need. Although 40 % of all epilepsy cases are thought to have acquired causes, there is a roadblock for successful prevention. Efforts to protect the brain from epileptogenic insults are severely hampered by our lack of biomarkers to identify the few percent at high risk meriting treatment among those exposed. Preventing brain injury has been moderately effective from around birth to middle age; however, the strategy has failed to stop a substantial increase over the last decades in symptomatic epilepsy in those aged 65 and above. The traditional concept of repurposing anti-seizure drugs used for symptomatic seizure relief to prevent the onset of epilepsy has completely failed up to now. More recently, however, hope is on the horizon with a search for biomarkers and discovery of a new class of agents, called anti-epileptogenic drugs, which were specifically developed for prevention of epilepsy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Orrin Devinsky, Annamaria Vezzani, … Piero Perucca

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Löscher W, Brandt C. Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol Rev. 2010;62:668–700.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Dichter MA. Emerging concepts in the pathogenesis of epilepsy and epileptogenesis. Arch Neurol. 2009;66:443–7.

    Article  PubMed  Google Scholar 

  3. Löscher W, Hirsch LJ, Schmidt D. The enigma of the latent period in the development of symptomatic acquired epilepsy—traditional view versus new concepts. Epilepsy Behav. 2015;52(Pt A):78–92. An important article about the latent period as a window of therapeutic opportunity for preventions trial in epilepsy.

    Article  PubMed  Google Scholar 

  4. Sloviter RS, Bumanglag AV. Defining “epileptogenesis” and identifying “antiepileptogenic targets” in animal models of acquired temporal lobe epilepsy is not as simple as it might seem. Neuropharmacology. 2012;69:3–15.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Temkin NR. Preventing and treating posttraumatic seizures: the human experience. Epilepsia. 2009;50 Suppl 2:10–3.

    Article  PubMed  Google Scholar 

  6. Löscher W, Klitgaard H, Twyman RE, Schmidt D. New avenues for antiepileptic drug discovery and development. Nat Rev Drug Discov. 2013;12:757–76.

    Article  PubMed  Google Scholar 

  7. Dreifuss FE. Prevention as it pertains to epilepsy. Arch Neurol. 1995;52(4):363–6.

    Article  CAS  PubMed  Google Scholar 

  8. Sillanpää M, Gissler M, Schmidt D. Efforts in epilepsy prevention in the last 40 years: lessons from a large nationwide study. JAMA Neurol. 2016;73(4):390–5. An important article showing that we failed to prevent epilepsy in people below age 65 and a massive increase in epilepsy in the elderly.

    Article  PubMed  Google Scholar 

  9. Agostini M. The prevention of epilepsy. JAMA Neurol. 2016;73(4):375–610.

    Article  PubMed  Google Scholar 

  10. Herman ST. Clinical trials for prevention of epileptogenesis. Epilepsy Res. 2006;68:35–8.

    Article  PubMed  Google Scholar 

  11. Sloviter RS. Progress on the issue of excitotoxic injury modification vs. real neuroprotection; implications for post-traumatic epilepsy. Neuropharmacology. 2011;61(5-6):1048–50.

    Article  CAS  PubMed  Google Scholar 

  12. Mani R, Pollard J, Dichter MA. Human clinical trials in antiepileptogenesis. Neurosci Lett. 2011;497(3):251–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Schmidt D. Is antiepileptogenesis a realistic goal in clinical trials? Concerns and new horizons. Epilept Disord. 2012;14:105–13.

    Google Scholar 

  14. Pitkänen A, Engel Jr J. Past and present definitions of epileptogenesis and its biomarkers. Neurotherapeutics. 2014;11(2):231–41.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Pitkänen A, Löscher W, Vezzani A, et al. Advances in the development of biomarkers for epilepsy. Lancet Neurol. 2016;15(8):843–56. A good overview showing where how we stand in the discovery of biomarkers for epilepsy development.

    Article  PubMed  Google Scholar 

  16. Baulac M, de Boer H, Elger C, et al. Epilepsy priorities in Europe: a report of the ILAE-IBE Epilepsy Advocacy Europe Task Force. Epilepsia. 2015;56(11):1687–95.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Schmidt D. Chapter 5 antiepileptic drug development. In: Shorvon SD, Perucca E, Engel Jr J, editors. Treatment of epilepsy. 4th ed. Newark: Wiley-Blackwell; 2015. p. 61–74.

    Chapter  Google Scholar 

  18. Schmidt D, Friedman D, Dichter MA. Anti-epileptogenic clinical trial designs in epilepsy: issues and options. Neurotherapeutics. 2014;11(2):401–11.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dieter Schmidt.

Ethics declarations

Conflict of Interest

Dieter Schmidt and Matti Sillanpää declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Epilepsy

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schmidt, D., Sillanpää, M. Prevention of Epilepsy: Issues and Innovations. Curr Neurol Neurosci Rep 16, 95 (2016). https://doi.org/10.1007/s11910-016-0695-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11910-016-0695-9

Keywords

Navigation